References
- S. Stewart, I. Ekman, T. Ekman, A. Oden and A. Rosengren, Population impact of heart failure and the most common forms of cancer: a study of 1 162 309 hospital cases in Sweden (1988 to 2004), Circ. Cardiovasc. Qual. Outcomes 3(6) (2010) 573–580; https://doi.org/10.1161/CIRCOUTCOMES.110.957571
- T. A. McDonagh, M. Metra, M. Adamo, R. S. Gardner, A. Baumbach, M. Böhm, H. Burri, J. Butler, J. Čelutkienė, O. Chioncel, J. G. F. Cleland, A. J. S. Coats, M. G. Crespo-Leiro, D. Farmakis, M. Gi-lard, S. Heymans, A. W. Hoes, T. Jaarsma, E. A. Jankowska and A. K. Skibelund, 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure, Eur. Heart J. 42(36) (2021) 3599–3726; https://doi.org/10.1093/eurheartj/ehab368
- E. Lonn, Dose response of ACE inhibitors: implications of the SECURE trial, Trials 2(4) (2001) 155–159; https://doi.org/10.1186/cvm-2-4-155
- D. S. Roffman, High-versus low-dose ACE inhibitor therapy in chronic heart failure. Ann. Pharmacother. 38(5) (2004) 831–838; https://doi.org/10.1345/aph.1C402
- E. R. Debusmann, J. O. Pujadas, W. Lahn, R. Irmisch, F. Jane, T. S. Kuan, J. Mora, U. Walter, H. G. Eckert, P. Hajdu and H. Metzger, Influence of renal function on the pharmacokinetics of ramipril (HOE 498), Am. J. Cardiol. 59(10) (1987) 70D–78D; https://doi.org/10.1016/0002-9149(87)90057-9
- J. M. van Griensven, R. C. Schoemaker, A. F. Cohen, H. G. Luus, M. Seibert-Grafe and H. J. Rothig, Pharmacokinetics, pharmacodynamics and bioavailability of the ACE inhibitor ramipril, Eur. J. Clin. Pharmacol. 47(6) (1995) 513–518. https://doi.org/10.1007/BF00193704
- D. G. Levitt and R. C. Schoemaker, Human physiologically based pharmacokinetic model for ACE inhibitors: ramipril and ramiprilat, BMC Clin. Pharmacol. 6(1) (2006); https://doi.org/10.1186/1472-6904-6-1
- B. Beermann, O. Nyquist, C. Hoglund, K. A. Jacobsson, U. Naslund and M. Jensen-Urstad, Acute haemodynamic effects and pharmacokinetics of ramipril in patients with heart failure. A placebo controlled three-dose study, Eur. J. Clin. Pharmacol 45(3) (1993) 241–246; https://doi.org/10.1007/BF00315390
- H. Schunkert, J. Kindler, M. Gassmann, W. Lahn, R. Irmisch, E. Ritz, E. R. Debusmann, J. O. Puja das, K. M. Koch and H. G. Sieberth, Pharmacokinetics of ramipril in hypertensive patients with renal insufficiency, Eur. J. Clin. Pharmacol. 37(3) (1989) 249–256; https://doi.org/10.1007/BF00679779
- M. Verho, C. Luck, W. J. Stelter, B. Rangoonwala and N. Bender, Pharmacokinetics, metabolism and biliary and urinary excretion of oral ramipril in man, Curr. Med. Res. Opin. 13(5) (1995) 264–273; https://doi.org/10.1185/03007999509111551
- U. Gerckens, E. Grube, T. Mengden, H. Sigel, W. L. Wagner, T. Lahn, R. Irmisch and H. Metzger, Pharmacokinetic and pharmacodynamic properties of ramipril in patients with congestive heart failure (NYHA III-IV), J. Cardiovasc. Pharmacol. 13 Suppl 3 (1989) S49–51; https://doi.org/10.1097/00005344-198900133-00012
- B. Heintz, M. Verho, D. Brockmeier, G. Luckel, S. Maigatter, H. G. Sieberth, B. Rangoonwala and N. Bender, Multiple-dose pharmacokinetics of ramipril in patients with chronic congestive heart failure, J. Cardiovasc. Pharmacol. 22 Suppl 9 (1993) S36–42.
- G. Loncar, J. Springer, M. Anker, W. Doehner and M. Lainscak, Cardiac cachexia: hic et nunc, J. Cachexia Sarcopenia Muscle 7(3) (2016) 246–60; https://doi.org/10.1002/jcsm.12118
- S. Khan and A. Shahzadi, Clinical pharmacokinetics of drugs in cardiopulmonary associated cachexia without hepatorenal pathology: a systematic review, Drug Metab. Rev. 51(1) (2019) 1–11. https://doi.org/10.1080/03602532.2018.1508226
- K. Trobec, M. Kerec Kos, S. von Haehling, J. Springer, S. D. Anker and M. Lainscak, Pharmacokinetics of drugs in cachectic patients: a systematic review, PLoS One 8(11) (2013) e79603 (10 pages); https://doi.org/10.1371/journal.pone.0079603
- S. Janmahasatian, S. B. Duffull, S. Ash, L. C. Ward, N. M. Byrne and B. Green, Quantification of lean bodyweight, Clin. Pharmacokinet. 44(10) (2005) 1051–1065; https://doi.org/10.2165/00003088-200544100-00004
- L. I. Cortinez, B. J. Anderson, N. H. Holford, V. Puga, N. de la Fuente, H. Auad, S. Solari, F. A. Allende and M. Ibacache, Dexmedetomidine pharmacokinetics in the obese. Eur. J. Clin. Pharmacol. 71(12) (2015) 1501–1508; https://doi.org/10.1007/s00228-015-1948-2
- I. Janssen, R. N. Baumgartner, R. Ross, I. H. Rosenberg and R. Roubenoff, Skeletal muscle cut-points associated with elevated physical disability risk in older men and women, Am. J. Epidemiol. 159(4) (2004) 413–421; https://doi.org/10.1093/aje/kwh058
- I. Janssen, S. B. Heymsfield, R. N. Baumgartner and R. Ross, Estimation of skeletal muscle mass by bioelectrical impedance analysis, J. Appl. Physiol. 89(2) (2000) 465–471; https://doi.org/10.1152/jappl.2000.89.2.465
- O. González, M. E. Blanco, G. Iriarte, L. Bartolomé, M. I. Maguregui and R. M. Alonso, Bioanalytical chromatographic method validation according to current regulations, with a special focus on the non-well defined parameters limit of quantification, robustness and matrix effect, J. Chromatogr. A 1353 (2014) 10–27; https://doi.org/10.1016/j.chroma.2014.03.077
- C. Ghosh, Relative matrix effects: A step forward using standard line slopes and ANOVA analysis, Arab. J. Chem. 12(7) (2019) 1378–1386; https://doi.org/10.1016/j.arabjc.2014.11.019
- A. M. Alvarez and D. Mukherjee, Liver abnormalities in cardiac diseases and heart failure, Int. J. Angiol. 20(3) (2011)135–142; https://doi.org/10.1055/s-0031-1284434
- M. D. Samsky, C. B. Patel, T. A. DeWald, A. D. Smith, G. M. Felker, J. G. Rogers and A. F. Hernandez, Cardiohepatic interactions in heart failure: an overview and clinical implications, J. Am. Coll. Cardiol. 61(24) (2013) 2397–2405; https://doi.org/10.1016/j.jacc.2013.03.042
- T. Narumi, T. Watanabe, S. Kadowaki, T. Takahashi, M. Yokoyama, D. Kinoshita, Y. Honda, A. Funayama, S. Nishiyama, H. Takahashi, T. Arimoto, T. Shishido, T. Miyamoto and I. Kubota, Sarcopenia evaluated by fat-free mass index is an important prognostic factor in patients with chronic heart failure, Eur. J. Intern. Med. 26(2) (2015) 118–122; https://doi.org/10.1016/j.ejim.2015.01.008
- N. H. Uszko-Lencer, F. Bothmer, P. E. van Pol and A. M. Schols, Measuring body composition in chronic heart failure: a comparison of methods, Eur. J. Heart Fail 8(2) (2006) 208–214; https://doi.org/10.1016/j.ejheart.2005.07.007
- P. L. Toutain and H. P. Lefebvre, Pharmacokinetics and pharmacokinetic/pharmacodynamic relationships for angiotensin-converting enzyme inhibitors, J. Vet. Pharmacol. Ther. 27(6) (2004) 515–525; https://doi.org/10.1111/j.1365-2885.2004.00601.x
- R. Thomsen, H. B. Rasmussen, K. Linnet and INDICES Consortium, In vitro drug metabolism by human carboxylesterase 1: focus on angiotensin-converting enzyme inhibitors, Drug Metab. Dispos. 42(1) (2014) 126–133; https://doi.org/10.1124/dmd.113.053512
- W. J. Gilchrist, K. Beard, P. Manhem, E. M. Thomas, J. I. Robertson and S. G. Ball, Pharmacokinetics and effects on the renin-angiotensin system of ramipril in elderly patients, Am. J. Cardiol. 59(10) (1987) 28D–32D; https://doi.org/10.1016/0002-9149(87)90049-X
- R. Ogawa, J. M. Stachnik and H. Echizen, Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 2, drugs administered orally), Clin. Pharmacokinet. 53(12) (2014) 1083–1114; https://doi.org/10.1007/s40262-014-0189-3